Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 19/20 | 0.63 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21359519 | 0.90 | OGA (0.76) | OGAOPRK1 | |
| SCHEMBL21369551 | 0.90 | OGA (0.76) | OGAOPRK1 | |
| SCHEMBL16112851 | 0.89 | OGA (0.72) | OGAOPRK1 | |
| SCHEMBL16112513 | 0.85 | OGA (0.67) | OGA | |
| SCHEMBL16114036 | 0.83 | OGA (0.64) | OGAOPRK1 | |
| SCHEMBL16114058 | 0.82 | OGA (0.62) | OGAOPRK1 | |
| SCHEMBL21359571 | 0.81 | OGA (0.67) | OGAOPRK1 | |
| SCHEMBL21369426 | 0.81 | OGA (0.67) | OGAOPRK1 | |
| SCHEMBL22412852 | 0.81 | OGA (0.55) | OGAOPRK1 | |
| SCHEMBL16112487 | 0.81 | OGA (0.69) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421224-B2 | Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20220259197-A1 | AZETIDINYL O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3935055-A1 | AZETIDINYL 0-GLYC0PR0TEIN-2-ACETAMID0-2-DEOXY-3-D-GLUC0PYRAN0SIDASE INHIBITORS | Biogen MA Inc. (US) | 2022-01-12 | — | — | EP | disclosed |
| WO-2020185593-A1 | AZETIDINYL 0-GLYC0PR0TEIN-2-ACETAMID0-2-DEOXY-3-D-GLUC0PYRAN0SIDASE INHIBITORS | BIOGEN MA INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020185593-A1 | AZETIDINYL 0-GLYC0PR0TEIN-2-ACETAMID0-2-DEOXY-3-D-GLUC0PYRAN0SIDASE INHIBITORS | BIOGEN MA INC. (US) | 2020-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259197-A1 | AZETIDINYL O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | MAN2A1, UGGT1, MGAT3 | OGA 77/4885OPRK1 2586/4885 |
| US-12421224-B2 | Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | UGGT1, MAN2A1, MAN2B2 | OGA 61/4885OPRK1 2262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.